The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.

The submission is supported by Phase IIIb APEX trial results showing Tremfya reduced symptoms and inhibited structural progression in biologic-naïve patients with active psoriatic arthritis.

Explore the potential of GLP-1 receptor agonists for rheumatoid arthritis. Learn about their safety, benefits, and what to consider before starting these medications.

Synovitis is significantly more likely among patients with psoriasis, and it is more likely among those with PsA than PsO.

A growing number of women with chronic inflammatory diseases are continuing to use TNF inhibitors throughout pregnancy.

Tildrakizumab is an interleukin-23 antagonist approved under the brand name Ilumya for the treatment of plaque psoriasis.

Q2 2025 Earnings Call Transcript July 16, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.77, ...

While Stelara is used in fewer indications than Humira, it commands a large market share in its therapeutic areas, most ...

Self-care methods for psoriatic arthritis (PsA) include staying active with gentle exercises, getting enough sleep, and ...

Mease described guselkumab (Tremfya, Janssen) as a fully human monoclonal antibody that selectively targets the interleukin (IL)-23p19 subunit, which may inhibit IL-23 signaling.

Metabolic syndrome is common in psoriatic arthritis and is a known risk factor for worse symptoms and poor treatment outcomes. This study sought to explore the syndrome's role in a more precisely ...